Nirvana Life Sciences Inc. (CSE: NIRV) (Nirvana or the “Company”), a Canadian based life sciences company aimed at developing non-addictive chronic pain and relapse preventing products is pleased to announce the appointment of Mr. Jakson Inwentash to the Company’s Board of Directors.
Vancouver, British Columbia--(Newsfile Corp. - May 3, 2022) - Nirvana Life Sciences Inc. (CSE: NIRV) (Nirvana or the “Company”), a Canadian based life sciences company aimed at developing non-addictive chronic pain and relapse preventing products is pleased to announce the appointment of Mr. Jakson Inwentash to the Company’s Board of Directors.
Mr. Inwentash is a Director and VP Investments at ThreeD Capital, where he focuses on identifying, researching, and meeting with early-stage companies in various disruptive industries as investment targets. He is also a registered Dealer Representative and has a successful track record of raising capital in industries such as mining, battery recycling, organic food, high performance computing, biotechnology and blockchain.
Mr. Inwentash has significant capital markets experience; he is an advisor to and a board member of several private and publicly listed companies. Jakson Inwentash holds a BBA from the University of Miami and, in 2020, completed his Certified Financial Analyst (“CFA”) designation.
Mr. Inwentash commented, “I am very excited to join the Board of Nirvana Life Sciences. This company has extremely interesting research and development in the non-addictive pain management and relapse prevention space, which is more important than ever as we continue to deal with the opioid crisis. I believe with Nirvana’s incredible leadership; we can help to provide safer and more sustainable medicines to millions of people worldwide. I look forward to leveraging my experience to assist the company in its mission.”
Mr. Bruce Clark, Chief Executive Officer of Nirvana commented, “We are pleased that Mr. Inwentash has chosen to join our Board, he brings a strong understanding of the value that alternative therapies can play in the treatment of addiction and management of chronic pain. His involvement will be impactful as we move to capitalize on this opportunity.”
For further information:
Bruce Clark- CEO
info@nirvanalifescience.com
Phone: 604-401-8100
About Nirvana Life Sciences Inc.
Nirvana Life Sciences Inc. has been founded with a simple objective of researching and developing non-addictive pain management and relapse prevention products that can provide healthier outcomes for patients who live with chronic pain and/or have battled with addiction. Nirvana believes that using naturally sourced psychedelics in novel formulations holds the promise of delivering non-addictive solutions that are effective in managing pain and addiction. Nirvana’s team, consisting of leading researchers from around the globe, will develop therapies that have the potential of freeing millions from addiction and saving society billions of dollars annually.
Forward-Looking Statements
This news release contains certain forward-looking statements and forward-looking information (collectively referred to herein as “forward- looking statements”) within the meaning of Canadian securities laws including, without limitation, statements with respect to the future investments by the Company. All statements other than statements of historical fact are forward-looking statements. Undue reliance should not be placed on forward-looking statements, which are inherently uncertain, are based on estimates and assumptions, and are subject to known and unknown risks and uncertainties (both general and specific) that contribute to the possibility that the future events or circumstances contemplated by the forward-looking statements will not occur. Although the Company believes that the expectations reflected in the forward-looking statements contained in this press release, and the assumptions on which such forward-looking statements are made, are reasonable, there can be no assurance that such expectations will prove to be correct. Readers are cautioned not to place undue reliance on forward-looking statements included in this document, as there can be no assurance that the plans, intentions or expectations upon which the forward-looking statements are based will occur. By their nature, forward-looking statements involve numerous assumptions, known and unknown risks and uncertainties that contribute to the possibility that the predictions, forecasts, projections and other forward-looking statements will not occur, which may cause the Company’s actual performance and results in future periods to differ materially from any estimates or projections of future performance or results expressed or implied by such forward-looking statements. The forward-looking statements contained in this news release are made as of the date hereof and the Company does not undertake any obligation to update publicly or to revise any of the included forward-looking statements, except as required by applicable law. The forward-looking statements contained herein are expressly qualified by this cautionary statement.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/122565
